Skip to content Skip to footer
A steadier labor market, cooler-than-expected inflation, fresh consumer purchasing power, evolving digital-advertising models and disciplined corporate cost management are creating a more constructive backdrop for equities. The economy is not behaving like a fireworks display, but for investors that may be the…
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has delivered the kind of Phase 3 result biotechnology investors wait patiently—and, on occasion, not so patiently—for. The company reported that avexitide reduced the composite rate of severe and clinically meaningful post-bariatric hypoglycemia events by 55% versus…